Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that the Company’s registrational Phase 2b trial of its novel radiotherapeutic candidate, AZEDRA® ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE